HLA-DRB1*01:03 Identifies a Severe IBD Phenotype : Lancet Gastroenterol Hepatol | June 2026

Introduction:

Inflammatory bowel disease (IBD) exhibits marked heterogeneity in disease behavior, progression, and treatment response. Identifying genetic markers associated with aggressive disease could facilitate earlier risk stratification and personalized therapeutic strategies. Among genetic factors, the HLA-DRB1*01:03 allele has long been linked to severe ulcerative colitis, but its broader impact across the spectrum of IBD has remained incompletely understood.

Problem Statement:

Although HLA-DRB1*01:03 is recognized as a susceptibility allele in ulcerative colitis, it is unclear whether this genetic variant influences long-term disease severity, surgical risk, treatment requirements, and adverse outcomes across both ulcerative colitis and Crohn’s disease. A comprehensive evaluation of its genotype–phenotype associations could help identify patients at risk for a more aggressive disease course.

Summary:

This large genotype–phenotype association study involving more than 43,000 patients with IBD provides compelling evidence that HLA-DRB101:03 is a marker of severe disease across both ulcerative colitis and Crohn’s disease. Carriers of this allele demonstrated higher rates of major adverse outcomes, including colectomy in ulcerative colitis, colonic resection in Crohn’s disease, and perianal disease in both conditions. Importantly, the genetic association extended beyond disease occurrence to disease trajectory, with carriers developing complications earlier and requiring advanced therapies sooner than non-carriers. The study also showed that HLA-DRB101:03 was associated with an increased likelihood of advanced therapy failure, suggesting a potentially more treatment-resistant disease phenotype. Notably, the allele was linked to younger-onset ulcerative colitis and distinct disease characteristics in Crohn’s disease, further supporting its role in shaping disease behavior. These findings position HLA-DRB101:03 as one of the strongest genetic markers currently associated with adverse IBD outcomes. From a clinical perspective, genetic identification of HLA-DRB101:03 carriers could eventually support precision medicine approaches by identifying patients who may benefit from closer monitoring, earlier introduction of advanced therapies, and proactive management strategies. Although further validation and cost-effectiveness analyses are required before routine implementation, this study represents an important step toward genotype-guided risk stratification in IBD.